GLP-1 medications can help people lose weight by influencing appetite, satiation, and digestion
Rapid synaptic plasticity of glutamatergic synapses on dopamine neurons in the ventral tegmental area in response to acute amphetamine injection
But for people with commercial coverage, copays could be as low as $25 a month with an Eli Lilly savings card
Phase 1b (CT-388, 24 weeks): Phase 2 (CT-388 up to 24 mg, 48 weeks): GI AEs described as "mild-to-moderate" and "generally consistent with incretin class" Discontinuation due to AEs: 5.9% (vs 1.3% placebo) Weight loss: 22.5% placebo-adjusted at 48 weeks Key characteristics: Phase 1b showed very high absolute GI rates during titration, but these declined substantially during maintenance Phase 2 data showed a much more favorable tolerability profile with a low discontinuation rate of 5.9% The signal-biased design appears to provide sustained receptor activation without desensitization Despite high initial GI rates, very few patients discontinued, suggesting events were transient and manageable Phase 3 (ENITH program) planned for 2026 Bioglutide (NA-931)# Bioglutide is the first oral quadruple receptor agonist (GLP-1, GIP, glucagon, and IGF-1), developed by Biomed Industries
And then, carbohydrates can help you fall asleep
Available online at: 147 WangZ.XiaoY.ChenW.TangK.ZhangL